Article

Daily Medication Pearl: Glecaprevir and Pibrentasvir (Mavyret) for Hepatitis C

Mavyret is indicated for the treatment of patients with chronic hepatitis C virus without cirrhosis or with compensated cirrhosis.

Medication Pearl of the Day: Glecaprevir and Pibrentasvir (Mavyret)

Indication: Mavyret is a fixed-dose combination of glecaprevir and pibrentasvir, indicated for the treatment of adult and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype (GT) 1, 2, 3, 4, 5 or 6 infections without cirrhosis or with compensated cirrhosis.

Insight:

  • Dosing: Three tablets taken at the same time orally once daily (total daily dose: glecaprevir 300 mg and pibrentasvir 120 mg) with food.
  • Dosage form: Tablets 100 mg glecaprevir and 40 mg pibrentasvir. Oral pellets 50 mg glecaprevir and 20 mg pibrentasvir.
  • Adverse events (AEs): In patients receiving Mavyret, the most reported AEs (greater than 10%) are headache and fatigue.
  • Mechanism of action: Mavyret is a fixed-dose combination of glecaprevir, an HCV NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor.
  • Manufacturer: AbbVie

Sources:

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Phone call, pharmacist woman and writing on medicine checklist, customer service or virtual pharmacy support. Serious doctor with medical notes, health insurance documents and talking at help desk
Washington D.C., USA - March 1, 2020: American Institute of Pharmacy Building in Washington, D.C., United States, the first-established professional society of pharmacists in the United States.
American Captial Building.
© 2025 MJH Life Sciences

All rights reserved.